Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma

A Phase Ib Study of the VEGF Receptor Tyrosine Kinase Inhibitor Tivozanib and Modified FOLFOX-6 in Patients With Advanced Gastrointestinal Malignancies

(2015) Corina N. Oldenhuis et al.   Clinical Colorectal Cancer

Lessons From Anti–Vascular Endothelial Growth Factor and Anti–Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma

(2015) Christine Lu-Emerson et al.   JOURNAL OF CLINICAL ONCOLOGY

Neural network alterations underlie cognitive deficits in brain tumor patients

(2014) Jolanda Derks et al.   CURRENT OPINION IN ONCOLOGY

Comparative Evaluation of Registration Algorithms in Different Brain Databases With Varying Difficulty: Results and Insights

(2014) Yangming Ou et al.   IEEE TRANSACTIONS ON MEDICAL IMAGING

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

(2014) Walter Taal et al.   LANCET ONCOLOGY

Vessel calibre—a potential MRI biomarker of tumour response in clinical trials

(2014) Kyrre E. Emblem et al.   Nature Reviews Clinical Oncology

Modern network science of neurological disorders

(2014) Cornelis J. Stam   NATURE REVIEWS NEUROSCIENCE

A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer

(2013) Erica L. Mayer et al.   BREAST CANCER RESEARCH AND TREATMENT

Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI

(2013) Robert J. Harris et al.   JOURNAL OF NEURO-ONCOLOGY

Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy

(2013) Kyrre E Emblem et al.   NATURE MEDICINE

Local MEG networks: The missing link between protein expression and epilepsy in glioma patients?

(2013) L. Douw et al.   NEUROIMAGE

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation

(2013) T. T. Batchelor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MR Imaging Predictors of Molecular Profile and Survival: Multi-institutional Study of the TCGA Glioblastoma Data Set

(2013) David A. Gutman et al.   RADIOLOGY

Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

(2012) Dmitry A. Nosov et al.   JOURNAL OF CLINICAL ONCOLOGY

Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors

(2011) F. A. L. M. Eskens et al.   CLINICAL CANCER RESEARCH

On the scope and interpretation of the Tofts models for DCE-MRI

(2011) Steven P. Sourbron et al.   MAGNETIC RESONANCE IN MEDICINE

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer

(2010) D. G. Duda et al.   ONCOLOGIST

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

(2009) Andrew X. Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice

(2009) Walid S. Kamoun et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY